Earendil Labs Raises USD 787 Million to Scale AI-Driven Biologics Discovery
Earendil Labs will use its USD 787 million financing to scale its Artificial Intelligence (AI)-driven R&D platform, expand inter-disciplinary teams and advance a pipeline of antibody and biologics programmes targeting serious diseases.
Inter-disciplinary Teams | 21/03/2026 | By News Bureau | 256
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy